
---
title: '康泰生物重组腺病毒载体新冠疫苗在印尼获批作为同源加强针'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=516'
author: 证券时报网
comments: false
date: Tue, 11 Jan 2022 22:17:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=516'
---

<div>   
<p>证券时报e公司讯，<a class="trsHotWords" href="http://info.stcn.com/dc/stock/?stockcode=SZ300601" style="color: #2f67d1;text-decoration: none;" code="300601" target="_blank">康泰生物</a>消息，日前，印尼药物与食品监管局(BPOM)授予<a class="trsHotWords" href="http://info.stcn.com/dc/stock/?stockcode=SZ300601" style="color: #2f67d1;text-decoration: none;" code="300601" target="_blank">康泰生物</a>生产的重组腺病毒载体新冠疫苗Kconecavac作为同源加强针的紧急使用授权。</p>

                  
</div>
            